The Regulatory System May Not Be Ready for Synthetic Organisms
By Susana Medeiros,
RegBlog
| 07. 15. 2015
Untitled Document
Scientists are working on synthetically designed microorganisms that may soon produce everything from the fuel in your gas tank to your Spandex. Distinct from genetically modified organisms, which are created by the transfer of small amounts of genetic material, synthetic biology allows scientists to assemble entirely new organisms that may be more efficient than those naturally occurring in nature.
Some of these organisms can even function as tiny factories to produce rare and expensive chemicals and compounds. For example, Exxon expects to spend over $600 million towards the development of synthetic algae that may serve as an alternative biofuel over the next decade. Synthetic organisms could even be designed specifically to be released into the environment and consume carbon dioxide, mollifying the effects of global warming.
However, despite its potential advantages, synthetic biology could also produce dangers that are not met by the nation’s current regulatory system, according to a recent article by law professors Gregory N. Mandel and Gary E. Marchant.
Synthetic biology is currently regulated based on its use, typically by the U.S. Environmental Protection...
Related Articles
By Anna Louie Sussman, The New York Times | 08.21.2026
Since in vitro fertilization was invented nearly 50 years ago, at least 10 million children who would not otherwise exist have been brought into the world. New constellations of families — older moms, same-sex parents, single dads — have flourished...
By Jenni Fink, Newsweek | 08.19.2026
“Donald Trump” by Gage Skidmore is licensed under CC BY-SA 2.0
President Donald Trump's latest effort to limit birthright citizenship could have consequences for the international surrogacy industry, potentially affecting thousands of intended parents from overseas who travel...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...
By Claire Robinson and Jonathan Matthews, Guest Contributors
| 08.25.2026
This is an excerpt of an article originally published on August 1, 2026 at GMWatch.
A six-year-old girl has died in a gene editing gene therapy trial in China that went wrong, the journal Science reports. Seven days after the girl's medical team infused trillions of viruses carrying the recipe for the gene editing tool – in this case a base editor – into her spinal fluid, she died of a severe immune reaction linked to the therapy.
Just...